Current treatment of low grade gliomas

Memo - Magazine of European Medical Oncology

Volumn 5, Issue 3, 2012, Pages 223-227

  Van Den Bent, Martin J ^a   Snijders, Tom J ^b   Bromberg, Jacoline E C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Astrocytoma; Chemotherapy; Low grade glioma; Oligodendroglioma; Radiotherapy; Surgery; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ASTROCYTOMA; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; EARLY INTERVENTION; GLIOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; THERAPY DELAY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84874110301     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-012-0014-3     Document Type: Review

References (41)

1. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol. 1997;56:1098-1104.
2. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-18.
3. Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in suspected versus proven low-grade gliomas. Neurology. 2001;56:618-23.
4. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442-8.
5. Surma-aho O, Niemelä M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285-90.
6. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338-45.
7. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg. 1993;79:533-6.
8. Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524-8.
9. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 2011;13:307-16.
10. Brasil CG, Ciccarelli O, Altmann DR, et al. Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. 2009;253:505-12.
11. Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol. 2009;11:176-82.
12. Van Den Bent MJ, Afra D, De Witte O, et al. Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of lowgrade astrocytoma and oligodendroglioma in the adult. Lancet. 2005;366:985-90.
13. Taphoorn MJB, Klein Schiphorst A, Snoek FJ, et al. Cognitive functions and quality of life in patients with lowgrade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48-54.
14. Correa DD, Shi W, Thaler HT, et al. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86:321-7.
15. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet. 2002;360:1361-8.
16. Rees J, Watt H, Jager HR, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2008;21(1):54-64.
17. Soffietti R, Borgogne M, Ducati A, et al. Efficacy of radiation therapy on seizures in low-grade astrocytomas. Neuro-Oncology. 2005;7:389 (abstract #422, abstr).
18. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with lowgrade gliomas. J Neurosurg. 2008;108:227-35.
19. Pignatti F, Van Den Bent MJ, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-84.
20. Shaw E, Arusell RM, Scheithauer B, et al. A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma: initial report of a NCCTG-RTOG-ECOG study. J Clin Oncol. 2002;20:2267-76.
21. Brown PD, Buckner JC, O'Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiation Oncol Biol Phys. 2004;59:117-25.
22. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109:817-24.
23. Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 2011;81:218-24.
24. Floeth FW, Pauleit D, Sabel M, et al. Prognostic Value of O-(2-18 F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. J Nucl Med. 2007;48:519-27.
25. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109:835-41.
26. Gunnarsson T, Olafsson E, Sighvatsson V, et al. Surgical treatment of patients with low-grade astrocytomas and medically intractable seizures. Acta Neurol Scand. 2002;105:289-92.
27. Duffau H, Capelle L, Lopes M, et al. Medically intractable epilepsy from insular low-grade gliomas: improvement after an extended lesionectomy. Acta Neurochir (Wien). 2002;144:563-72.
28. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120:719-29.
29. Stockhammer F, Misch M, Helms HJ, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21(3):194-7.
30. Duffau H, Lopes M, Arthuis F, et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry. 2005;76:845-51.
31. Claus E, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magentic resonance image guidance. Cancer. 2005;103:1227-33.
32. Chang EF, Clark A, Smith JS, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011;114:566-73.
33. Karim ABMF, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 2284. Int J Radiation Oncol Biol Phys. 1996;36:549-56.
34. Shaw EG, Wang M, Coons S, et al. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). Proc Am Soc Clin Oncol. 2008;26 (abstract 2006, abstr).
35. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol. 2010;12:1078-82.
36. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-6.
37. Van Den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583-93.
38. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95:87-93.
39. Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251-5.
40. Biemond-ter Stege E, Kros JM, de Bruin HG, et al. Treatment of low grade oligodendroglial tumors with PCV chemotherapy. Cancer. 2005;103:802-9.
41. Taal W, Dubbink HJ, Zonnenberg CB, et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol. 2011;13:235-41.